The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats

被引:29
作者
Jia, L [1 ]
Blantz, RC [1 ]
机构
[1] Univ Calif San Diego, Vet Affairs Med Ctr, Sch Med, Div Nephrol Hypertens, San Diego, CA 92161 USA
关键词
S-nitrosocaptopril; captopril; nitric oxide (NO); glomerular filtration rate; mean arterial pressure; Goldblatt hypertensive rat;
D O I
10.1016/S0014-2999(98)00424-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present investigation was performed to evaluate the effects of S-nitrosocaptopril, a novel vasodilator possessing the capacities of both an angiotensin converting enzyme inhibitor and an NO donor, on blood pressure and renal function in rats. S-nitrosocaptopril produced acute reductions in mean arterial pressure after both oral dosing (5, 10, 50 mg/kg) to chronically-catheterized awake rats and intravenous administrations (0.125, 1.25, 12.5 mg/kg) to anesthetized rats. The hypotensive magnitude and duration of S-nitrosocaptopril were dose-dependent. Acute pressure-associated reductions in the glomerular filtration rate and urine flow were observed only at high concentration of S-nitrosocaptopril (12.5 mg/kg, i.v.) in both awake and anesthetized rats. These decreases were transient, followed by an overshoot of glomerular filtration rate and urine flow above basal values. In contrast, captopril (i.v.) did not produce any significant acute effects on mean blood pressure and glomerular filtration rate in either awake or anesthetized rats. In rats with acute hypertension induced by N-G-monomethyl-L-arginine (L-NMMA, 30 mg/kg, i.v.), S-nitrosocaptopril (0.125 mg/kg, i.v.) significantly abolished the hypertensive effects. In contrast, the hypertension was not affected by captopril. In two-kidney one-clipped Goldblatt hypertensive rats, oral administration of S-nitrosocaptopril (25 mg/kg, b.i.d.) for 10 days significantly reduced systolic blood pressure and preserved glomerular filtration rate. The oral antihypertensive effect of S-nitrosocaptopril was more potent than captopril (P < 0.05). In conclusion, these findings indicate that: (1) S-nitrosocaptopril provides both acute and chronic anti-hypertensive effects orally and intravenously, whereas captopril has only moderate chronic oral effects; and (2) S-nitrosocaptopril preferentially decreases blood pressure without markedly affecting glomerular filtration rate. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:33 / 41
页数:9
相关论文
共 29 条
[11]  
KRIPALANI KJ, 1980, FED PROC, V39, P307
[12]  
LI J, 1993, J PHARMACOL EXP THER, V267, P371
[13]  
LIN MJ, 1998, ACTA PHARMACOL SINIC, V19, P321
[14]  
LOSCALZO J, 1989, J PHARMACOL EXP THER, V249, P726
[15]  
MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529
[16]   CAPTOPRIL - PHARMACOLOGY, METABOLISM, AND DISPOSITION [J].
MIGDALOF, BH ;
ANTONACCIO, MJ ;
MCKINSTRY, DN ;
SINGHVI, SM ;
LAN, SJ ;
EGLI, P ;
KRIPALANI, KJ .
DRUG METABOLISM REVIEWS, 1984, 15 (04) :841-869
[17]   VASORELAXANT PROPERTIES OF THE ENDOTHELIUM-DERIVED RELAXING FACTOR MORE CLOSELY RESEMBLE S-NITROSOCYSTEINE THAN NITRIC-OXIDE [J].
MYERS, PR ;
MINOR, RL ;
GUERRA, R ;
BATES, JN ;
HARRISON, DG .
NATURE, 1990, 345 (6271) :161-163
[18]  
NAKAE I, 1995, J PHARMACOL EXP THER, V274, P40
[20]   Reversing endothelial dysfunction with ACE inhibitors - A new trend? [J].
Rajagopalan, S ;
Harrison, DG .
CIRCULATION, 1996, 94 (03) :240-243